Core Technology Platform
AIDEN
Shaperon maximizes the efficiency of small molecule and protein drug development by leveraging its AI-powered drug discovery platform, AIDEN (AI-driven Drug ENgagement). AIDEN is trained on a vast dataset of over 240 million small-molecule compounds, protein structures, and biological activity profiles, enabling the precise and rapid identification and optimization of promising drug candidates. Compared to traditional experimental screening methods, AIDEN significantly improves the efficiency of candidate selection, dramatically reducing both development time and cost.
- [AI-driven small molecule drug development]
- AIDEN utilizes a variety of predictive and generative models to identify compounds optimized for specific targets. Through more than 10 advanced algorithms, it predicts critical drug characteristics such as efficacy, absorption, distribution, metabolism, excretion, and toxicity (ADMET), achieving up to 96% accuracy. Based on these predictive insights, AIDEN also generates optimal compounds, enabling a more than 50% reduction in the time and cost required for drug candidate discovery.
- [AI-driven NanoMab drug development]
- Shaperon is capable of performing the entire end-to-end process of NanoMab development in-house, and actively leverages AI technologies to optimize each stage. By utilizing its AIDEN platform, the company has built a system that precisely predicts binding structures and affinities with target proteins, aiming to reduce the Nanobody generation timeline from several months to within two weeks. This approach significantly enhances the efficiency of Nanobody-based drug development and boosts overall research productivity.
